Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 133

References for PMC Articles for PubMed (Select 20649427)

1.

Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy.

Metzner KJ, Rauch P, von Wyl V, Leemann C, Grube C, Kuster H, Böni J, Weber R, Günthard HF.

J Infect Dis. 2010 Apr 1;201(7):1063-71. doi: 10.1086/651136.

2.

Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study.

Stringer JS, McConnell MS, Kiarie J, Bolu O, Anekthananon T, Jariyasethpong T, Potter D, Mutsotso W, Borkowf CB, Mbori-Ngacha D, Muiruri P, Ong'ech JO, Zulu I, Njobvu L, Jetsawang B, Pathak S, Bulterys M, Shaffer N, Weidle PJ.

PLoS Med. 2010 Feb 16;7(2):e1000233. doi: 10.1371/journal.pmed.1000233.

3.

Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.

Halvas EK, Wiegand A, Boltz VF, Kearney M, Nissley D, Wantman M, Hammer SM, Palmer S, Vaida F, Coffin JM, Mellors JW.

J Infect Dis. 2010 Mar;201(5):672-80. doi: 10.1086/650542.

4.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA 3rd, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team.

J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543.

5.

Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.

Sax PE, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, Godfrey C, Jahed NC, Myers L, Katzenstein D, Farajallah A, Rooney JF, Ha B, Woodward WC, Koletar SL, Johnson VA, Geiseler PJ, Daar ES; AIDS Clinical Trials Group Study A5202 Team.

N Engl J Med. 2009 Dec 3;361(23):2230-40. doi: 10.1056/NEJMoa0906768. Epub 2009 Dec 1.

6.

Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211.

Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, Han D, Flexner C, Wilkin TJ, Skolnik PR, Greaves WL, Kuritzkes DR, Reeves JD; AIDS Clinical Trials Group A5211 Team.

J Infect Dis. 2009 Dec 1;200(11):1724-8. doi: 10.1086/648090.

7.

Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.

Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD; International AIDS Society-USA.

Top HIV Med. 2008 Aug-Sep;16(3):266-85.

PMID:
19856548
8.

Transmission of drug-resistant HIV-1 is stabilizing in Europe.

Vercauteren J, Wensing AM, van de Vijver DA, Albert J, Balotta C, Hamouda O, Kücherer C, Struck D, Schmit JC, Asjö B, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Grossman Z, Horban A, Korn K, Kostrikis L, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Riva C, Ruiz L, Salminen M, Schuurman R, Sonnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher CA.

J Infect Dis. 2009 Nov 15;200(10):1503-8. doi: 10.1086/644505.

9.

Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.

Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):569-73. doi: 10.1097/QAI.0b013e3181ba11e8.

PMID:
19779307
10.

Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitors.

Varghese V, Shahriar R, Rhee SY, Liu T, Simen BB, Egholm M, Hanczaruk B, Blake LA, Gharizadeh B, Babrzadeh F, Bachmann MH, Fessel WJ, Shafer RW.

J Acquir Immune Defic Syndr. 2009 Nov 1;52(3):309-15. doi: 10.1097/QAI.0b013e3181bca669.

11.

The remarkable frequency of human immunodeficiency virus type 1 genetic recombination.

Onafuwa-Nuga A, Telesnitsky A.

Microbiol Mol Biol Rev. 2009 Sep;73(3):451-80, Table of Contents. doi: 10.1128/MMBR.00012-09. Review.

12.

Low-abundance HIV drug-resistant viral variants in treatment-experienced persons correlate with historical antiretroviral use.

Le T, Chiarella J, Simen BB, Hanczaruk B, Egholm M, Landry ML, Dieckhaus K, Rosen MI, Kozal MJ.

PLoS One. 2009 Jun 29;4(6):e6079. doi: 10.1371/journal.pone.0006079.

13.

Sensitive detection of the K103N non-nucleoside reverse transcriptase inhibitor resistance mutation in treatment-naïve HIV-1 infected individuals by rolling circle amplification.

Wang B, Dwyer DE, Chew CB, Kol C, He ZP, Joshi H, Steain MC, Cunningham AL, Saksena NK.

J Virol Methods. 2009 Oct;161(1):128-35. doi: 10.1016/j.jviromet.2009.06.004. Epub 2009 Jun 11.

PMID:
19523982
14.

Lower risk of resistance after short-course HAART compared with zidovudine/single-dose nevirapine used for prevention of HIV-1 mother-to-child transmission.

Lehman DA, Chung MH, Mabuka JM, John-Stewart GC, Kiarie J, Kinuthia J, Overbaugh J.

J Acquir Immune Defic Syndr. 2009 Aug 15;51(5):522-9. doi: 10.1097/QAI.0b013e3181aa8a22.

15.

Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection.

Salazar-Gonzalez JF, Salazar MG, Keele BF, Learn GH, Giorgi EE, Li H, Decker JM, Wang S, Baalwa J, Kraus MH, Parrish NF, Shaw KS, Guffey MB, Bar KJ, Davis KL, Ochsenbauer-Jambor C, Kappes JC, Saag MS, Cohen MS, Mulenga J, Derdeyn CA, Allen S, Hunter E, Markowitz M, Hraber P, Perelson AS, Bhattacharya T, Haynes BF, Korber BT, Hahn BH, Shaw GM.

J Exp Med. 2009 Jun 8;206(6):1273-89. doi: 10.1084/jem.20090378. Epub 2009 Jun 1.

16.

Increased detection of HIV-1 drug resistance at time of diagnosis by testing viral DNA with a sensitive assay.

Ellis GM, Page LC, Burman BE, Buskin S, Frenkel LM.

J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):283-9. doi: 10.1097/QAI.0b013e3181a9972c.

PMID:
19398922
17.

Prevalence of minor variants of HIV strains at reverse transcriptase position 103 in therapy-naïve patients and their impact on the virological failure.

Balduin M, Oette M, Däumer MP, Hoffmann D, Pfister HJ, Kaiser R.

J Clin Virol. 2009 May;45(1):34-8. doi: 10.1016/j.jcv.2009.03.002. Epub 2009 Apr 17.

PMID:
19375978
18.

Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes.

Simen BB, Simons JF, Hullsiek KH, Novak RM, Macarthur RD, Baxter JD, Huang C, Lubeski C, Turenchalk GS, Braverman MS, Desany B, Rothberg JM, Egholm M, Kozal MJ; Terry Beirn Community Programs for Clinical Research on AIDS.

J Infect Dis. 2009 Mar 1;199(5):693-701. doi: 10.1086/596736.

19.

Detection of human immunodeficiency virus (HIV) type 1 M184V and K103N minority variants in patients with primary HIV infection.

Toni TA, Asahchop EL, Moisi D, Ntemgwa M, Oliveira M, Masquelier B, Brenner BG, Wainberg MA.

Antimicrob Agents Chemother. 2009 Apr;53(4):1670-2. doi: 10.1128/AAC.01494-08. Epub 2009 Jan 26.

20.

Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy.

Coovadia A, Hunt G, Abrams EJ, Sherman G, Meyers T, Barry G, Malan E, Marais B, Stehlau R, Ledwaba J, Hammer SM, Morris L, Kuhn L.

Clin Infect Dis. 2009 Feb 15;48(4):462-72. doi: 10.1086/596486.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk